Novel therapeutic agents for osteosarcoma

References

• Link MP, Gebhardt MC, Meyers PA. Osteosarcoma. In: Principles and Practice of Pediatric Oncology (4th Edition). Pizzo PA, Poplack DG (Eds.). Lippincott Williams & Wilkins, PA, USA 1051–1080 (2002).
   Google Scholar
• Li FP, Fraumeni JF Jr, Mulvihill JJ et al. A cancer family syndrome in twenty-four kindreds. Cancer Res.48, 5358–5362 (1988).
   PubMed Web of Science ®Google Scholar
• Wong FL, Boice JD, Abramson DH et al. Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. JAMA278, 1262–1267 (1997).
   PubMed Web of Science ®Google Scholar
• Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N. Engl. J. Med.341(5), 342–352 (1999).
   PubMed Web of Science ®Google Scholar
• Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist9(4), 422–441 (2004).
   PubMed Web of Science ®Google Scholar
• Meyers PA, Gorlick R. Osteosarcoma. Pediatr. Clin. North Am.44(4), 973–989 (1997).
   PubMed Web of Science ®Google Scholar
• Link MP, Goorin AM, Miser AW et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N. Engl. J. Med.314(25), 1600–1606 (1986).
   PubMed Web of Science ®Google Scholar
• Eilber FR, Rosen G. Adjuvant chemotherapy for osteosarcoma. Semin. Oncol.16(4), 312–322 (1989).
   PubMed Web of Science ®Google Scholar
• Glasser DB, Lane JM, Huvos AG, Marcove RC, Rosen G. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer69(3), 698–708 (1992).
   PubMed Web of Science ®Google Scholar
• Gorlick R, Meyers PA. Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specific. J. Pediatr. Hematol. Oncol.25(11), 840–841 (2003).
   PubMed Web of Science ®Google Scholar
• Kempf-Bielack B, Bielack SS, Jurgens H et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J. Clin. Oncol.23, 559–568 (2005).
   PubMed Web of Science ®Google Scholar
• Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here? Paediatr. Drugs10(5), 315–327 (2008).
   PubMedGoogle Scholar
• Woods, KA, Camacho-Hubner C, Savage MO et al. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N. Engl. J. Med.335, 1363–1367 (1996).
   PubMed Web of Science ®Google Scholar
• Abuzzahab MJ, Schneider A, Goddard A et al. IGF-1 receptor mutations resulting in intrauterine and postnatal growth retardation. N. Engl. J. Med.349, 2211–2222 (2003).
   PubMed Web of Science ®Google Scholar
• Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr. Relat. Cancer13(Suppl. 1), S33–S43 (2006).
   PubMed Web of Science ®Google Scholar
• Ma J, Pollak MN, Giovannucci E et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl Cancer Inst.91, 151–156 (1999).
   PubMedGoogle Scholar
• Chan JM, Stampfer MJ, Giovannucci E et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science279, 563–566 (1998).
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Willett WC, Colditz GA et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet351, 1393–1396 (1998).
   PubMed Web of Science ®Google Scholar
• Yu H, Spitz MR, Mistry J et al. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case–control analysis. J. Natl Cancer Inst.91, 151–156 (1999).
   PubMed Web of Science ®Google Scholar
• Pollak MN, Polychronakos C, Richard M. Insulin like growth factor I: a potent mitogen for human osteogenic sarcoma. J. Natl Cancer Inst.82, 301–305 (1990).
   PubMedGoogle Scholar
• Ouban A, Muraca P, Yeatman T et al. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum. Pathol.34, 803–808 (2003).
   PubMed Web of Science ®Google Scholar
• Shimizu C, Hasegawa T, Tani Y et al. Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum. Pathol.35, 1537–1542 (2004).
   PubMedGoogle Scholar
• Sekyi-Out A, Bell RS, Ohashi C, Pollak M, Andrulis IL. Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. Cancer Res.55, 129–134 (1995).
   PubMedGoogle Scholar
• Kaleko M, Rutter WJ, Miller D. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol. Cell Biol.10, 464–473 (1990).
   PubMed Web of Science ®Google Scholar
• Mansky PJ, Liewehr DJ, Steinberg SM et al. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. J. Pediatr. Hematol. Oncol.24, 440–446 (2002).
   PubMed Web of Science ®Google Scholar
• Benini S, Baldini N, Manara MC et al. Redundancy of autocrine loops in human osteosarcoma cells. Int. J. Cancer80, 581–588 (1999).
   PubMed Web of Science ®Google Scholar
• Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol. Cancer Ther.6(1), 1–11 (2007).
   PubMed Web of Science ®Google Scholar
• Ji QS, Mulvihill M, Rosenfeld-Franklin M et al. Preclinical characterization of OSI-906: a novel IGF-1R kinase inhibitor in clinical trials. Presented at: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics Meeting Abstracts. San Francisco, CA, USA, 22–26 October 2007 (Abstract C192).
   Google Scholar
• Kolb EA, Gorlick R, Houghton PJ et al. Initial testing (stage 1) of a monoclonal antibody (SCH717454) against the IGF-1 receptor by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer50, 1190–1197 (2008).
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Rothenberg ML, Rodon J et al. A Phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J. Clin. Oncol.25(18 Suppl.), S118 (2007).
   PubMedGoogle Scholar
• Haluska P, Shaw HM, Batzel GN et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin. Cancer Res.13(19) 5834–5840 (2007).
   PubMed Web of Science ®Google Scholar
• Rodon J, Patnaik A, Stein M et al. A Phase I study of q3W R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist in patients with advanced solid tumors. Presented at: AACR-NCI-EORTC International Conference: Molectular Targets and Cancer Therapeutics. San Francisco, CA, USA, 22–26 October 2007.
   Google Scholar
• Hudis C. Trastuzumab – mechanism of action and use in clinical practice. N. Engl. J. Med.357, 39–51 (2007).
   PubMed Web of Science ®Google Scholar
• Onda M, Matsuda S, Higaki S et al. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer77, 71–78 (1996).
   PubMed Web of Science ®Google Scholar
• Yarden Y. The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur. J. Cancer37(Suppl. 4), S3–S8 (2001).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Lewin WJ, Ulrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science235, 177–182 (1987).
   PubMed Web of Science ®Google Scholar
• Wright C, Angus B, Nicholson S et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res.49, 2087–2090 (1989).
   PubMed Web of Science ®Google Scholar
• Hynes NE. Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Sem. Cancer Biol.4, 19–26 (1993).
   PubMed Web of Science ®Google Scholar
• Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J. Pediatr. Hematol. Oncol.25, 27–32 (2003).
   PubMed Web of Science ®Google Scholar
• Akatsuka T, Wada T, Kokai Y et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer94, 1397–1404 (2002).
   PubMed Web of Science ®Google Scholar
• Gorlick R, Huvos AG, Heller G et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J. Clin. Oncol.17, 2781–2788 (1999).
   PubMed Web of Science ®Google Scholar
• Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. Cell surface expression of epidermal growth factor receptor and HER-2 with nuclear expression of HER-4 in primary osteosarcoma. Cancer Res.64, 2047–2053 (2004).
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Manara MC, Hattinger CM et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing’s sarcoma. Eur. J. Cancer41, 1349–1361 (2004).
   Google Scholar
• Somers GR, Ho M, Zielenska M, Squire JA, Thorner PS. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr. Dev. Pathol.8, 525–532 (2005).
   PubMed Web of Science ®Google Scholar
• Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L. Absence of HER2 /neu gene expression in osteosarcoma and skeletal Ewing’s sarcoma. Clin. Cancer Res.8, 788–793 (2002).
   PubMed Web of Science ®Google Scholar
• Maitra A, Wanzer D, Weinber AG, Ashfaq R. Amplification of the HER-2 /neu oncogene is uncommon in pediatric osteosarcomas. Cancer92, 677–683 (2001).
   PubMed Web of Science ®Google Scholar
• Kilpatrick SE, Geisinger KR, King TS et al. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod. Pathol.14, 1277–1283 (2001).
   PubMed Web of Science ®Google Scholar
• Anninga JK, van der Vijver MJ, Cleton-Jansen AM et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur. J. Cancer40, 963–970 (2004).
   PubMed Web of Science ®Google Scholar
• McGary EC, Weber K, Mills L et al. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin. Cancer Res.8, 3584–3591 (2002).
   PubMed Web of Science ®Google Scholar
• Sulzbacher I, Traxler M, Mosberger I, Lang S, Chott A. Platelet-derived growth factor-AA and -α receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod. Pathol.13, 632–637 (2000).
   PubMed Web of Science ®Google Scholar
• Kubo T, Piperdi S, Rosenblum J et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer112(10), 2119–2129 (2008).
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Cioffi CL, Law N et al. Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther.295, 39–145 (2000).
   Google Scholar
• Bond M, Bernstein ML, Pappo A et al. A Phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children’s Oncology Group study. Pediatr. Blood Cancer50, 254–258 (2008).
   PubMed Web of Science ®Google Scholar
• Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer7(4), 295–308 (2007).
   PubMed Web of Science ®Google Scholar
• Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer4, 335–348 (2004).
   PubMed Web of Science ®Google Scholar
• Bjornsti MA and Houghton PJ. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer4, 335–348 (2004).
   PubMed Web of Science ®Google Scholar
• Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist12, 1007–1018 (2007).
   PubMed Web of Science ®Google Scholar
• Wan X, Mendoza A, Khanna C, Helman LJ. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res.65, 2406–2411 (2005).
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Morton CL, Kolb EA et al. Initial testing (Stage 1) of the mTOR inhibitor rapamycin by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer50, 799–805 (2008).
   PubMed Web of Science ®Google Scholar
• Mita M, Rowinsky E, Mita A et al. A Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of AP23573, an mTOR inhibitor administered IV daily × 5 every other week in patients with refractory or advanced malignancies. J. Clin. Oncol.22(Suppl. 14), 3076a (2004).
   Google Scholar
• Chawla SP, Tolcher AW, Staddon AP et al. Updated results of a Phase II trial of AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcoma. J. Clin. Oncol.24(Suppl. 18), 9505a (2006).
   Google Scholar
• Raymond E, Alexandre J, Faivre S et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with cancer. J. Clin. Oncol.22, 2336–2347 (2004).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol.22, 909–918 (2004).
   PubMed Web of Science ®Google Scholar
• Chan S, Scheulen ME, Johnston S et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol.23, 5314–5322 (2005).
   PubMed Web of Science ®Google Scholar
• Witzig TE, Geyer Sm, Ghobrial I et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol.23, 5347–5356 (2005).
   PubMed Web of Science ®Google Scholar
• O’Donnell A, Faivre S, Judson I et al. A Phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumors. Proc. Am. Soc. Clin. Oncol.22, 803a (2003).
   Google Scholar
• Amato RJ, Misellati A, Khan M et al. A Phase II trial of RAD001 in patients with metastatic renal cell carcinoma (MRCC). J. Clin. Oncol.24(Suppl. 18), 4530a (2006).
   Google Scholar
• Hudes G, Carducci M, Tomczak P et al. A Phase III, randomized, 3-arm study of temsirolimus (TERSR) or interferon-α (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. J. Clin. Oncol.24(Suppl. 18), LBA4a (2006).
   Google Scholar
• Fouladi M, Laningham F, Wu J et al. Phase I study of everolimus in pediatric patients with refractory solid tumors. J. Clin. Oncol.25, 4806–4812 (2007).
   PubMed Web of Science ®Google Scholar
• O’Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res.66(3), 1500–1508 (2006).
   PubMed Web of Science ®Google Scholar
• Strong JE, Coffey MC, Tang D, Sabininin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO17(12), 3351–3362 (1998).
   PubMed Web of Science ®Google Scholar
• Brose MS, Volpe P, Feldman M et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res.62, 6997–7000 (2002).
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature417, 949–954 (2002).
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol.9(7), 517–531 (2008).
   PubMed Web of Science ®Google Scholar
• Vidal L, Pandha H, Spicer J et al. A Phase I study of Reolysin given intravenously to patients with advanced malignancies. 2006 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol.24(18 Suppl.), 3064 (2006).
   Google Scholar
• Gollamudi R, Desai K, Chaudhary I et al. Pharmacodynamic and safety study of Reolysin in patients with advanced solid tumors. 2007 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol.25 (18S), 14004 (2007).
   Google Scholar
• Zhang WE, Kolb EA. Reolysin, and unmodified reovirus, has significant anti-tumor activity in childhood sarcomas. Presented at: The AACR 97th Annual Meeting 2006. Washington, DC, USA, 1–5 April 2006 (Abstract 4331).
   Google Scholar
• Soefje SA, Sarantopoulos J, Sankhala KK, Mita AC. A Phase II study of intravenous Reolysin (wild-type reovirus) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. J. Clin. Oncol.20, 10568 (2008).
   Google Scholar
• Maki, RG. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist12, 999–1006 (2007).
   PubMed Web of Science ®Google Scholar
• Leu KM, Ostruszka LJ, Shewach et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J. Clin. Oncol.22, 1706–1712 (2004).
   PubMed Web of Science ®Google Scholar
• Navid F, Willert JR, McCarville MB et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer113(2), 419–425 (2008).
   PubMed Web of Science ®Google Scholar
• Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. N. Engl. J. Med.11, 5–14 (1996).
   Google Scholar
• Guo W, Healey JH, Meyers PA et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin. Cancer Res.5, 621–627 (1999).
   PubMed Web of Science ®Google Scholar
• Trippett T, Meyers P, Gorlick R, Steinherz P, Wollner N, Bertino JR. High dose trimetrexate with leucovorin protection in recurrent childhood malignancies: a Phase II trial. Presented at: The 35th ASCO Annual Meeting. Atlanta, GA, USA, 15–18 May 1999 (Abstract 889).
   Google Scholar
• Shih C, Chen VJ, Gossett LS et al. LY231514, a pyrrolo[2,3-D]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res.57(6), 1116–1123 (1997).
   PubMed Web of Science ®Google Scholar
• Malempati S, Nicholson HS, Reid JM et al. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: The Children’s Oncology Group. J. Clin. Oncol.25, 1505–1511 (2007).
   PubMedGoogle Scholar
• Chou AJ, Bell MD, Mackinson C, Gupta R, Meyers PA, Gorlick R. Phase Ib/IIa study of sustained release lipid inhalation targeting cisplatin by inhalation in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol.25, 18S, 9525 (2007).
   Web of Science ®Google Scholar
• Chidiac T, Budd GT, Pelley R et al. Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas. Invest. New Drugs18, 253–259 (2000).
   PubMed Web of Science ®Google Scholar
• Judson I, Radford JA, Harris M et al. Randomised Phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer37, 870–877 (2001).
   PubMed Web of Science ®Google Scholar
• Muggia FM. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr. Oncol. Rep.3, 156–162 (2001).
   PubMedGoogle Scholar
• Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest.21, 167–176 (2003).
   PubMed Web of Science ®Google Scholar
• Alberts DS, Muggia FM, Carmichael J et al. Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials. Semin. Oncol.31, 53–90 (2004).
   PubMed Web of Science ®Google Scholar
• Diel IJ, Solomayer EF, Bastert G. Bisphosphonates and the prevention of metastasis: first evidence from preclinical and clinical studies. Cancer88, 3080–3088 (2005).
   Google Scholar
• O’Keefe RJ, Guise TA. Molecular mechanisms of bone metastasis and therapeutic implications. Clin. Orthop. Relat. Res.415(Suppl.), S100–S104 (2003).
   Google Scholar
• Ashton JA, Farese JP, Milner RJ, Lee‑Ambrose LM, van Gilder JM. Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs. Am. J. Vet. Res.66, 885–891 (2005).
   PubMed Web of Science ®Google Scholar
• Cheng YY, Huang L, Lee KM, Li K, Kumta SM. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr. Blood Cancer42, 410–415 (2004).
   PubMed Web of Science ®Google Scholar
• Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs12(5), 459–465 (2001).
   PubMed Web of Science ®Google Scholar
• Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer104, 2522–2529 (2005).
   PubMed Web of Science ®Google Scholar
• Healey J. The epidemic of chemotherapy-related osteoporosis. Curr. Opin. Orthop.10, 331–333 (1999).
   Google Scholar
• Jones DH, Nakashima T, Sanchez OH et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature440, 692–696 (2006).
   PubMed Web of Science ®Google Scholar
• Lipton A, Steger GG, Figeroa J et al. Randomized active-controlled Phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J. Clin. Oncol.25(28), 4431–4437 (2007).
   PubMed Web of Science ®Google Scholar
• Lipton A, Steger GG, Figueroa J et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin. Cancer Res.14(20), 6690–6696 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas D, Chawla SP, Skubitz K et al. Denosumab treatment of giant cell tumor of bone: interim analysis of an open-label Phase II study. J. Clin. Oncol.26(Suppl.), 10500 (2008).
   Google Scholar
• DuBois S, Demetri G. Markers of angiogenesis and clinical freatures in patients with sarcoma. Cancer109 (5), 813–819 (2007).
   PubMed Web of Science ®Google Scholar
• Maeda H, Chung Y, Ogawa Y et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer77, 858–863 (1996).
   PubMed Web of Science ®Google Scholar
• Ishigami SI, Arii S, Niwano M et al. Predictive value of VEGF in metastasis and prognosis of human colorectal cancer. Br. J. Cancer76, 418–422 (1998).
   Google Scholar
• Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Cancer79, 206–213 (1997).
   PubMed Web of Science ®Google Scholar
• Kaya M, Wada T, Akatsuka T et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin. Cancer Res.6, 572–577 (2000).
   PubMed Web of Science ®Google Scholar
• Charity RM, Foukas AF, Deshmukh NS, Grimer RJ. Vascular endothelial growth factor expression in osteosarcoma. Clin. Orthop. Relat. Res.448, 193–198 (2006).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Eng. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Maris JM, Courtright J, Houghton PJ et al. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr. Blood Cancer50, 581–587 (2008).
   PubMed Web of Science ®Google Scholar
• MacEwen EG, Kurzman ID, Rosenthal RC et al. Therapy of osteosarcoma in dogs with intravenous injection of liposome encapsulated muramyl tripeptide. J. Natl Cancer Inst.81, 935–936 (1989).
   PubMed Web of Science ®Google Scholar
• Kleinerman ES. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol. Oncol. Clin. North Am.9, 927–938 (1995).
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo M et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J. Clin. Oncol.23, 2004–2011 (2005).
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo MD et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival- a report from the Children’s Oncology Group. J. Clin. Oncol.26, 633–638 (2008).
   PubMed Web of Science ®Google Scholar
• Hunsberger S, Freidlin B, Smith M. Complexities in interpretation of osteosarcoma clinical trial results. J. Clin. Oncol.26(18), 3103–3104 (2008).
   PubMedGoogle Scholar
• Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte–macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA90, 3539–3543 (1993).
   PubMed Web of Science ®Google Scholar
• Anderson PM, Markovic SN, Sloan JA et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin. Cancer Res.5, 2316–2323 (1999).
   PubMed Web of Science ®Google Scholar
• Anderson P, Aguilera D, Pearson M, Woo S. Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents. Cancer Control15, 38–45 (2008).
   PubMedGoogle Scholar
• Anderson PM, Wiseman GA, Dispenzieri A et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J. Clin. Oncol.20, 189–196 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson PM, Wiseman GA, Erlandson L et al. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin. Cancer Res.11, 6895–6900 (2005).
   PubMed Web of Science ®Google Scholar
• Fagioli F, Aglietta M, Tienghi A et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian Sarcoma Group Study. J. Clin. Oncol.20, 2150–2156 (2002).
   PubMed Web of Science ®Google Scholar
• Sauerbrey A, Bielack S, Kempf-Bielack B et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplant.27, 933–937 (2001).
   PubMed Web of Science ®Google Scholar
• Fagioli F, Biasin E, Mereuta OM et al. Poor prognosis osteosarcoma: new therapeutic approach. Bone Marrow Transplant.41(Suppl.), S131–S134 (2008).
   Google Scholar